Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.
You may also be interested in...
Takeda’s TAK-875 Could Take On Other Oral Antidiabetics, Early Data Suggest
Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.
Early Signs For Takeda’s TAK-875 Suggest The GPR40 Agonist Could Take On Other Oral Antidiabetics
Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.
Dapagliflozin Faces Ominous Prospect Of New Trials
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.